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Despite recent advances in the treatment of metastatic
melanoma through targeted and immunotherapy, the
majority of patients do not achieve a durable response.
Research efforts to better understand responses are
underway, and numerous molecular mechanisms of
resistance to targeted therapy have been identified.
There is a growing appreciation of genomic heterogene-
ity as a contributor to resistance to therapy, although
immune heterogeneity has not been well characterized.
The goal of the present study is to better understand
genomic and immune heterogeneity in synchronous
metastases within melanoma patients, with the potential
to identify actionable strategies to overcome resistance.
In this study, we prospectively evaluated 36 tumors
from 16 melanoma patients (n=5 treatment-naïve, n=6
targeted therapy, n=5 immunotherapy). Distinct syn-
chronous metastases were evaluated by whole exome
sequencing and NanoString analysis and showed up to
36% tumor-specific mutations as well as significant dif-
ferences in expression of immune pathway effectors.
Accordingly, we performed immune profiling by flow
cytometry and immunohistochemistry demonstrating
significant immune heterogeneity between synchronous
melanoma tumors in all patients, most notably in the
CD4+ and CD8+ T cell compartment. Deep TCR
sequencing data revealed that T cell populations infil-
trating synchronous metastases presented different spe-
cificities, with less than 10% of T cell clones shared
between 2 tumors in the same patient. Additionally, the
NetMHC 3.4 algorithm revealed that 10-30% of pre-
dicted neoantigens were unique to individual tumors
and that over 10% of these presented high HLA-binding
affinity. Together, these data suggest significant genomic
and immune heterogeneity between synchronous metas-
tases in melanoma patients – not only in the setting of
therapy but also prior to its initiation. This has impor-
tant clinical implications, and could help explain vari-
able responses to therapy, however this hypothesis must
be tested carefully in a larger data set. Nonetheless,
these findings may have significant implications for the
treatment of melanoma and other cancers.
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